High-Elasticity Peptide-Enhanced HA
Engineered for architectural precision. G' of 400 Pa delivers structural definition and long-lasting volume in the most demanding aesthetic indications, with progressive bio-stimulation built in.
Request Clinical InformationELYARA Ultra is engineered for high-demand aesthetic applications where structural support and precise volumetric placement are paramount. The elevated G' of 400 Pa provides the lifting force required for deep tissue architecture while peptide integration ensures biological integration, not just volume.
Mid-face volumisation and cheekbone definition with natural projection.
Mandibular definition and lower face contouring with structural lift.
Vertical and horizontal chin augmentation for facial harmony.
Temporal hollowing correction for upper face volume restoration.
Retrograde injection along linear vectors to create defined structural planes. Ideal for jawline definition, nasolabial refinement, and creating directional lift across extended tissue planes.
Jawline, nasolabial folds, linear contouring
Perpendicular threading pattern creates a three-dimensional support matrix within the dermis. Provides widespread volumisation across larger treatment zones with even distribution.
Mid-face, cheeks, widespread volume
Discrete depot placement using small bolus volumes at precise anatomical landmarks. Delivers focused volumetric augmentation at specific projection points for architectural precision.
Chin, cheekbone apex, precise augmentation
Blunt-tip cannula delivery significantly reduces trauma, bruising, and vascular complication risk. Particularly advantageous in vascular risk zones and for patients with thin skin.
High-risk zones, sensitive patients, large areas
ELYARA Ultra is developed in advanced wound healing laboratories with biocompatibility at its core. Low BDDE residue and high-purity HA cross-linking minimise inflammatory response risk.
High-purity HA with low BDDE residue, designed for predictable tissue integration with minimal inflammatory response.
Full hyaluronic acid base allows prompt dissolution with hyaluronidase if clinical management is required.
Optimised rheology enables smooth extrusion and seamless tissue integration, minimising nodularity risk.
Transient events typically resolve within 24 to 72 hours. Patients may resume normal activities shortly after treatment. Minimal downtime in most cases.
Request clinical performance data, the full injection technique guide, and a sample kit for the ELYARA Dermal Filler Ultra. CE-approved structural filler with integrated peptide bio-stimulation. Available to accredited clinics.